Funding the development of functional cure therapies for T1D is the intended use of proceeds for ViaCyte’s latest financing, which it closed in June. ViaCyte closed the Series D with a final tranche of $45 million, bringing the total raised in this round to more than $115 million . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge